Compound 19A8.8

• Description:

  Compound 19A8.8 is a cyclic peptide derived from a CD36 protein fragment. Compound 19A8.8 inhibits the TGF-β/Smad3 signaling pathway by suppressing the interaction between TSP1 and CD36. Compound 19A8.8 has no obvious cytotoxicity. Compound 19A8.8 can be used for research on colon injury and fibrosis[1].

• UNSPSC:

  12352209

• Target:

  TGF-beta/Smad; TGF-β Receptor

• Related Pathways:

  Stem Cell/Wnt; TGF-beta/Smad

• Field of Research:

  Neurological Disease

• Smiles:

  O=C (N[C@@H] (CCC (O) =O) C (N[C@@H] (CCCNC (N) =N) C (N[C@@H] (C (C) C) C (N[C@@H] ([C@H] (O) C) C (N[C@@H] (CCC (N) =O) C (N[C@H]1CC (O) =O) =O) =O) =O) =O) =O) [C@H] (CCCCN) NC1=O

• Molecular Formula:

  C35H60N12O13

• Molecular Weight:

  856.92

• References & Citations:

  [1]Zhang W, et al. Design and discovery of novel cyclic peptides as TSP1-CD36 interaction inhibitors for intestinal fibrosis treatment. Bioorg Chem. 2025 Aug;163:108667.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported